Skip to main content

Partnering strategy

ReproNovo’s strategy is to forge impactful partnerships through both in-licensing and out-licensing collaborations. For advanced clinical programs, we seek strategic alliances to maximize the commercial potential of our current assets while actively pursuing in-licensing opportunities for earlier clinical-stage candidates (Phase 1 or later) in fertility and women’s health. Our expanding portfolio comprises novel therapeutic compounds designed to address critical gaps in male and female fertility as well as women’s health.

Commercial opportunities

With a proven track record in the design and execution of clinical development programs in reproductive medicine, our experienced team is positioned to drive innovation and deliver impactful solutions that improve fertility treatment outcomes and women’s health conditions. The potential of our assets captures commercial opportunities within the large and rapidly growing global markets for fertility treatments, assisted reproductive technologies (ART), and women’s health therapeutics.

RPN-001 (leflutrozole) a novel approach to male fertility

Addressing male-factor infertility associated with low testosterone

Infertility is a growing global crisis due to lifestyle, environmental and genetic causes. Approximately one in six people have experienced it at some point in their lives. At the same time, more and more people have access to modern treatment options to aid in conception. The reasons a couple may be unable to conceive are complex and establishing a thorough diagnosis is essential. Male-factor infertility is a contributing factor in around 50% of couples experiencing infertility. In recent years, the prevalence of low testosterone in men under 40 years has increased five-fold to 20-23%.

Whether the cause of a couple’s infertility lies with the male or the female partner, often they turn towards assisted reproductive technologies (ART), which in many cases mean in vitro fertilization (IVF). Alternative treatment options targeted directly to men could provide solutions to a significant number of couples seeking fertility. For infertile men with low testosterone and no or low sperm count, leflutrozole has the potential to become this alternative treatment option.

 

RPN-002 (nolasiban) a new molecular entity for embryo implantation and adenomyosis treatment

Improving success rates in assisted reproductive technologies (ART)

The implantation process following embryo transfer in an ART cycle is critical for treatment success. Establishing uterine quiescence during embryo implantation may increase pregnancy and live birth rates in ART treatments.

While many aspects of ART have advanced over time, therapies specifically designed to enhance embryo implantation are not yet available.

Addressing the unmet medical need in adenomyosis

Adenomyosis is a common uterine disorder, associated with painful symptoms such as severe menstrual cramps, heavy and prolonged periods and pain during intercourse. This condition is also accompanied by difficulties in conceiving. Abnormal uterine contractility is thought to be involved in the pathogenesis and progression of adenomyosis. Research has shown a link between oxytocin receptors and adenomyosis symptoms. This suggests that RPN-002, as an oxytocin receptor antagonist, could have a positive impact on women with this condition.

”

  • It’s difficult to watch my wife shoulder the burden of IVF treatment, the constant hormone shots and clinic visits. There is a constant battle between feeling full of guilt, helplessness and wanting to do more to support her through this journey. It’s not just about her physical discomfort or the financial strain; it’s about the emotional toll of watching the person I love endure so much for our dream of starting a family. Having a drug that I could take to improve my sperm count, would be a game-changer from my perspective.

    – Matt, male patient with secondary hypogonadism –

  • I have been through the emotional rollercoaster of IVF to turn my dream of having a baby into reality. Today, I am a proud mother of a two-year-old son. However, several treatment cycles failed, which was a crushing experience. The possibility of enhancing the chances of successful embryo implantation would fill many women with renewed hope.

    – Nicole, an IVF patient –

  • As someone living with the daily pain and challenges of adenomyosis, the need for treatment options is urgent and deeply personal. We deserve options that offer real relief and a chance to live without constant discomfort or having to make the agonizing decision to undergo a hysterectomy.

    – Sarah, who is suffering from adenomyosis –